OPTN_OUT_1 [2025-03-20 09:22:44 -0400] 1909 Bytes | 546 tokens | Cum: 546 tkns (6.83% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 09:22:43 AM on Thursday March 20, 2025 ET (UTC-0400), and I'm firing up the spotlight on OptiNose (OPTN), moving from 6 to 9.514. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for OptiNose:

C1 - Today 06:59AM - OptiNose climbs after take-private deal with Paratek Pharma
C2 - Mar-19-25 09:45PM - Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
C3 - Mar-19-25 09:45PM 09:25PM - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS)
C4 - Mar-11-25 04:15PM - Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
C5 - Jan-17-25 08:50AM - Optinose price target adjusted for stock split at Lake Street
C6 - Jan-15-25 07:00AM - Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
C7 - Dec-26-24 07:00AM - Optinose Announces 1-for-15 Reverse Stock Split
C8 - Dec-02-24 03:53PM - Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on OptiNose (OPTN)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

OPTN_OUT_3 [2025-03-20 09:22:51 -0400] 556 Bytes | 161 tokens | Cum: 709 tkns (8.86% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**OptiNose climbs after take-private deal with Paratek Pharma**
Date: Today 06:59AM
Source: (SeekingAlpha)
URL: https://seekingalpha.com/news/4422702-optinose-stock-climbs-ma-deal-with-paratek?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

Shares of OptiNose (NASDAQ:OPTN)climbed ~61%in the premarket on Thursday after the specialty pharmaceutical company agreed to be acquired by antibiotic drugmaker Paratek Pharmaceuticals in a take-private deal worth up to $330M.

-- More? (MOR) or Next section? (NEX)

OPTN_OUT_5 [2025-03-20 09:22:52 -0400] 996 Bytes | 303 tokens | Cum: 1121 tkns (14.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T12:09:53Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Aditxt (NASDAQ:ADTX), AEON Biopharma...
A2 - 2025-03-20T11:58:16Z - Paratek Pharmaceuticals (PRTK) to Acquire OptiNose (OPTN)...
A3 - 2025-03-20T09:53:33Z - US Stocks Likely To Open Higher As Fed Says Tariff-Induced Inflation Will Be 'Transitory:' Any Pullb...
A4 - 2025-03-20T10:06:05Z - Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Akebia Therap...
A5 - 2025-03-20T09:53:42Z - US Stocks Likely To Open Higher As Fed Says Tariff Induced Inflation Will Be 'Transitory:' Any Pullb...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OPTN_OUT_7 [2025-03-20 09:22:54 -0400] 967 Bytes | 314 tokens | Cum: 1437 tkns (17.96% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's Pre-Market Session - Aditxt (NASDAQ:ADTX), AEON Biopharma (AMEX:AEON)**Date: 2025-03-20Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44414692/12-health-care-stocks-moving-in-thursdays-pre-market-sessionGainers OptiNose OPTN shares moved upwards by 58.3% to $9.5 during Thursday's pre-market session. The market value of their outstanding shares is at $95.5 million. Windtree Therapeutics WINT stock increased by 35.5% to $2.29. The company's market cap stands at $1.7 million. Plus Therapeutics PSTV stock rose 20.99% to $0.62. The company's market cap stands at $3.6 million. MSP Recovery MSPR shares moved upwards by 15.56% to $1.63. The company's market cap stands at $3.4 million. AEON Biopharma AEON shares rose 13.01% to $0.85. Aditxt ADTX stock rose 12.96% to $11.33

-- More? (MOR) or Next section? (NEX)

OPTN_OUT_9 [2025-03-20 09:22:56 -0400] 997 Bytes | 304 tokens | Cum: 1743 tkns (21.79% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-20T01:45:00Z - Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
B2 - 2025-03-20T01:25:02Z - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
B3 - 2025-03-20T01:25:00Z - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
B4 - 2025-01-13T13:00:00Z - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
B5 - 2024-12-26T12:00:00Z - Optinose Announces 1-for-15 Reverse Stock Split
B6 - 2024-08-26T13:00:00Z - Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OPTN_OUT_11 [2025-03-20 09:23:10 -0400] 651 Bytes | 155 tokens | Cum: 1900 tkns (23.75% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/g44409180/paratek-pharmaceuticals-to-acquire-optinose-creating-significant-commercial-expansion-opportunitieParatek Pharmaceuticals announced it will acquire Optinose, including its approved product XHANCE, to expand its commercial portfolio and strengthen its position as a multi-product company focused on innovative specialty therapies.

-- More? (MOR) or Next section? (NEX)

OPTN_OUT_13 [2025-03-20 09:23:12 -0400] 554 Bytes | 161 tokens | Cum: 2309 tkns (28.86% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-20 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Agrmt and Plan of Merger

On March 19, 2025, OptiNose, Inc., a Delaware corporation (the Company), entered into an Agrmt and Plan of Merger (the Merger Agrmt) with Paratek Pharmaceuticals, Inc. (Paratek) and Orc...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

OPTN_OUT_15 [2025-03-20 09:23:14 -0400] 967 Bytes | 237 tokens | Cum: 2548 tkns (31.85% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

Agreement and Plan of Merger

On March 19, 2025, OptiNose, Inc., a Delaware corporation (the Company), entered into an Agreement and Plan of Merger (the Merger Agreement) with Paratek Pharmaceuticals, Inc. (Paratek) and Orca Merger Sub, Inc., a wholly owned subsidiary of Paratek (Merger Sub). Upon the terms and subject to the conditions set forth in the Merger Agreement, which has been unanimously adopted by the Board of Directors of the Company (the Board), Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Paratek (the Merger).

Pursuant to the Merger Agreement, upon the closing of the Merger (the Closing), each share of Company common stock issued and outstanding immediately prior to the Closing, other than shares owned by the Company (i

-- More? (MOR) or Next section? (NEX)

OPTN_OUT_17 [2025-03-20 09:23:16 -0400] 967 Bytes | 222 tokens | Cum: 2772 tkns (34.65% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ncluding held in the Companys treasury), Paratek, Merger Sub or any other wholly owned subsidiary of Paratek or the Company (which will be cancelled) and shares with respect to which appraisal rights are properly exercised and perfected and not effectively withdrawn under Delaware law, will automatically be converted into the right to receive (i) $9.00 in cash, without interest (the Cash Consideration) and (ii) one contractual contingent value right pursuant to the terms of the CVR Agreement (as defined and described below, a CVR) (together with the Cash Consideration, the Merger Consideration).

At or prior to the Effective Time, Parent and a rights agent will enter into the Contingent Value Rights Agreement in the form attached as Annex I to the Merger Agreement (the CVR Agreement).

At the effective time of the Merger (the Effective Time), each Pharmakon warrant (as defined the Merg

-- More? (MOR) or Next section? (NEX)

OPTN_OUT_19 [2025-03-20 09:23:37 -0400] 5863 Bytes | 1758 tokens | Cum: 4533 tkns (56.66% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+
| Volume: 20,824 | SMA50: 3.40% | Market Cap: 60.33M | Option/Short: No / Yes | Sales past 5Y: 22.26% | Sales Surprise: -10.96% |
+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+
| Avg Volume: 37.23K | SMA200: -43.74% | Shs Outstand: 10.06M | Short Float: 3.10% | Employees: 132 | EPS Surprise: 100.00% |
+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+
| Rel Volume: 0.56 | Perf Week: 9.69% | Shs Float: 7.85M | Short Ratio: 6.53 | Debt/Eq: - | P/E: - |
+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+
| RSI (14): 56.88 | Perf Month: 2.56% | Inst Own: 58.78% | Short Interest: 0.24M | Sales Y/Y TTM: 5.13% | Earnings: Nov 12 BMO |
+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+
| ATR (14): 0.46 | Perf Quarter: -15.07% | Insider Own: 21.94% | Beta: -0.60 | ROE: - | |
+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+
| SMA20: 7.57% | Index: - | Insider Trans: -0.81% | Sales Q/Q: 3.10% | ROI: - | |
+--------------------+-----------------------+-----------------------+------------------------+-----------------------+-------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: OptiNose, Inc. (OPTN) by Mahmoud Ramy A (Chief Executive Officer) on 2025-03-18
- Common Stock: 368 shares at $5.61 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Marino Michael F III (Chief Legal Officer & Corp Sec) on 2025-03-18
- Common Stock: 246 shares at $5.61 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Mahmoud Ramy A (Chief Executive Officer) on 2025-03-04
- Common Stock: 6376 shares at $5.29 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Marino Michael F III (Chief Legal Officer & Corp Sec) on 2025-03-04
- Common Stock: 2145 shares at $5.29 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Spence Paul Jr. (Chief Commercial Officer) on 2025-03-04
- Common Stock: 1223 shares at $5.29 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Spence Paul Jr. (Chief Commercial Officer) on 2025-02-21
- Common Stock: 17025 shares at $0 (D)
- Stock Option (Right to Buy): 8525 shares at $0 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Marino Michael F III (Chief Legal Officer & Corp Sec) on 2025-02-21
- Common Stock: 21150 shares at $0 (D)
- Stock Option (Right to Buy): 10575 shares at $0 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Kohler Terry (Chief Financial Officer) on 2025-02-21
- Common Stock: 13875 shares at $0 (D)
- Stock Option (Right to Buy): 6950 shares at $0 (D)

Inside Trans: OptiNose, Inc. (OPTN) by Mahmoud Ramy A (Chief Executive Officer) on 2025-02-21
- Common Stock: 53475 shares at $0 (D)
- Stock Option (Right to Buy): 26750 shares at $0 (D)

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: OptiNose, Inc. Common Stock
Market Cap: 60331800.0
Shares Outstanding: 10055300
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 75672000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -31148000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 6
Average Volume: 18806.5
30-Day High: 6
30-Day Low: 5.27

[Detailed Financials: Q3 2024]
- Total Assets: $131,020,000.0
- Total Liabilities: $172,117,000.0
- Total Equity: $-41,097,000.0
- Current Assets: $128,215,000.0
- Current Liabilities: $162,430,000.0

[Income Statement: Q3 2024]
- Revenue: $20,437,000.0
- Net Income: $467,000
- Operating Income: $-2,052,000.0
- Earnings Per Share (EPS): 0

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-8,861,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $131,872,000.0
- Total Liabilities: $174,725,000.0
- Total Equity: $-42,853,000.0
- Current Assets: $128,930,000.0
- Current Liabilities: $32,700,000.0

[Income Statement: Q2 2024]
- Revenue: $20,490,000.0
- Net Income: $-7,581,000.0
- Operating Income: $-6,548,000.0
- Earnings Per Share (EPS): -0.05

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $39,713,000.0
==== END OF FINANCIAL REPORT ====

OPTN_OUT_21 [2025-03-20 09:23:40 -0400] 561 Bytes | 131 tokens | Cum: 5001 tkns (62.51% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

OPTN_IN_23 [2025-03-20 09:23:40 -0400] 126 Bytes | 29 tokens | Cum: 5037 tkns (62.96% of 8k)
==========================================================================

====================================
[2025-03-20 06:23:40] # Analysis Completed
Elapsed Time: 58.23 seconds